	Gilead Sciences Estonia EFPIA Report 2022 Date of publication: 01/06/2023													
	Full name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	Unique country identifier OPTIONAL	Donations and Grants	Contribution to costs of Events			Fee for service and consultancy		vate of publication. of	201011. 01/ 00/ 2023	
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event		Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the		Total (optional)	
	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
HCP-s						N/A	N/A							
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons													
모	Aggregate amount attributable to transfers of value to such Recipients					N/A	N/A		5,509.47€	2,550.00€			8,059.47 €	
	Number of Recipients in aggregate disclosure					N/A	N/A		7	2			9	
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed					N/A	N/A		100%	100%			N/A	
	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
S-C	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons													
HCO-s	Aggregate amount attributable to transfers of value to such Recipients													
	Number of Recipients in aggregate disclosure													
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed													
	AGGREGATE DISCLOSURE													

8,059.47 €

Transfers of Value re Research & Development as defined

R&D